All In Biotech

Drug Trial Radar · NCT04325035

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)

Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Sep 28, 2020

Primary completion

Sep 26, 2024

Study completion Oct 30, 2024

Sponsor

Lead sponsor
Windtree TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Momentum Research, Inc.
First posted
Mar 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension.

Conditions

  • Cardiogenic Shock

Interventions

  • IstaroximeDrug

    Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion

  • PlaceboDrug

    Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in systolic blood pressure (SBP) area under the curve (AUC) 0-6Time frame: 0 to 6 hours after initiation of infusion

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Tufts Medical Center

    Boston, Massachusetts

  • Santorio de la Trinidad Palermo

    Buenos Aires, Argentina

  • Hospital Italiano de Bueno Aires

    Capital Federal, Buenos Aires, Argentina

  • Santorio Guemes

    Capital Federal, Buenos Aires, Argentina

  • Hospital Privado de Rosario

    Rosario, Sante Fe, Argentina

  • Instituto Cardiovascular de Rosario

    Rosario, Sante Fe, Argentina

  • Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo

    Alessandria, Italy

  • UOC Cardiologia, ASST degli Spedali Civili di Brescia Pizzale Spedali Civili 1

    Brescia, Italy

  • IRCCS San Raffaele Scientific Institute

    Milan, Italy

  • Uniwersytecki Szpital Kliniczny w Białymstoku

    Bialystok, Poland

  • Uniwersytecki Szpital Kliniczny w Opolu

    Opole, Poland

  • 4 Wojskowy Szpital Kliniczny

    Wroclaw, Poland

  • Uniwersytecki Szpital Kliniczny, Centrum Chorub Serca

    Wroclaw, Lower Silesian Voivodeship, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.